What Is Retatrutide? The Triple Agonist That Lost Participants 71 Pounds
Adrian Carter·Former metabolic disease researcher turned health writer. Breaks down how hormones like GLP-1 shape your weight, appetite, and energy — no jargon required.··9 min read
A drug still in clinical trials produced average weight losses of around 24% of body weight in 48 weeks. For someone weighing 295 pounds, that works out to roughly 71 pounds gone. The compound responsible is retatrutide, and it works by hitting three separate hormone receptors at once — a strategy no approved medication currently matches. This article breaks down exactly what retatrutide is, how its triple-receptor mechanism works, what the trial data actually say, and where the drug stands today.
What Is Retatrutide?
Retatrutide (development code LY3437943) is a synthetic peptide designed by Eli Lilly that simultaneously activates three hormone receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). That triple action is why researchers and science writers call it a "triple agonist." No currently approved weight-loss drug activates all three of these targets at the same time.
To appreciate why that triple mechanism matters, it helps to know what each receptor does on its own. GLP-1R is the target you may already recognize from semaglutide (the active ingredient in Ozempic and Wegovy) — it suppresses appetite and slows gastric emptying. GIPR, targeted by tirzepatide alongside GLP-1R, amplifies insulin release and adds another layer of satiety signaling. GCGR — the glucagon receptor — is the novel addition that the other approved drugs leave untouched.
Retatrutide is administered as a once-weekly subcutaneous injection, the same delivery method used for semaglutide and tirzepatide. Its half-life is approximately six days, which keeps blood levels stable between doses and makes weekly injections practical. The drug is currently in phase 3 clinical trials called the TRIUMPH program, launched in August 2023, and is not yet approved by any regulatory agency[6].
How Does Retatrutide Work?
Think of the three receptors as three separate volume knobs on a metabolic control panel. Most drugs turn up one knob. Tirzepatide, considered a major advance when it launched, turns up two. Retatrutide turns up all three simultaneously — and the evidence suggests the combined effect is meaningfully larger than the sum of the parts.
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
AC
Adrian Carter
Former metabolic disease researcher turned health writer. Breaks down how hormones like GLP-1 shape your weight, appetite, and energy — no jargon required.
Former metabolic disease researcher turned health writer. Breaks down how hormones like GLP-1 shape your weight, appetite, and energy — no jargon required.
retatrutidetriple agonistGLP-1weight loss
Related Articles
GIP glucagon
GLP-1 & Metabolics
Tirzepatide vs Semaglutide: Which GLP-1 Delivers Better Weight Loss Results?
Tirzepatide vs semaglutide: clinical trial data, side effects, costs, and how to choose the right GLP-1 for your weight loss goals.
Adrian Carter·9 min read
Here is how each pathway contributes. GLP-1R activation reduces appetite, slows the rate at which food leaves the stomach, and improves insulin secretion in a glucose-dependent way — meaning insulin goes up when blood sugar is high, not when it is already low. GIPR activation amplifies the insulin signal further and appears to support remodeling of fat tissue, helping the body shift away from storing calories. GCGR activation is where retatrutide separates itself from its predecessors: stimulating the glucagon receptor increases energy expenditure and promotes thermogenesis, meaning the body burns more calories even at rest[6].
Retatrutide's binding affinities reveal something deliberate about how Eli Lilly designed the molecule. It binds most tightly to the GIP receptor (EC50: 0.064 nM), then the GLP-1 receptor (EC50: 0.775 nM), then the glucagon receptor (EC50: 5.79 nM). The glucagon receptor is the weakest link by design — enough activation to boost energy expenditure without pushing blood glucose dangerously high, since glucagon normally raises blood sugar[6]. That calibration helps explain why the safety profile looked manageable in phase 2.
What Does the Research Actually Show?
The headline number comes from the pivotal phase 2 obesity trial published in the New England Journal of Medicine in 2023. In 338 adults with obesity, participants taking retatrutide 12 mg lost an average of 24.2% of their body weight over 48 weeks — and 83% of participants achieved at least a 15% weight loss[1]. To put that in context: the clinical threshold for a "highly effective" obesity drug is often set at 15%. At the top dose, retatrutide cleared that bar in more than four out of five people.
A separate phase 2 trial in The Lancet enrolled 281 people with type 2 diabetes — a group where weight-loss drugs often underperform compared to non-diabetic populations. Retatrutide 12 mg still produced a 16.94% body weight reduction at 36 weeks, plus a 2.02-percentage-point drop in HbA1c (glycated hemoglobin, a standard measure of long-term blood sugar control)[2]. The active-comparator arm using dulaglutide, a GLP-1 agonist already approved for type 2 diabetes, produced far smaller reductions on both measures.
A 2025 meta-analysis pooled data from three randomized controlled trials covering 878 patients and confirmed a mean weight reduction of 14.33% versus placebo, with reductions in BMI (5.38 kg/m2), waist circumference (10.51 cm), and systolic blood pressure (9.88 mmHg)[4]. A second meta-analysis covering four trials reached the same conclusion: dose-dependent weight loss with a safety profile comparable to control[5]. Liver fat data are equally striking. In a phase 2a trial enrolling 98 people with metabolic dysfunction-associated steatotic liver disease (MASLD) — a condition where excess liver fat can progress to cirrhosis — retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks, and 86% of that group reached a normal liver fat level below 5%[3]. Few pharmacological options have matched those numbers in MASLD.
Who Might Benefit?
The current trial data target four overlapping populations. First, people with obesity who have not achieved sufficient results with existing GLP-1 or dual agonist therapies. The 24.2% average weight loss at 48 weeks[1] exceeds published figures for tirzepatide at its highest dose (approximately 20.9% in the SURMOUNT-1 trial), though direct head-to-head comparisons have not been completed.
Second, people managing type 2 diabetes alongside obesity, where the HbA1c reduction of 2.02% alongside meaningful weight loss could reduce the need for additional diabetes medications[2]. Third, people with MASLD — often called fatty liver disease — who currently have limited pharmacological options and for whom the 82.4% liver fat reduction data are particularly relevant[3].
A fourth group worth noting is people with obesity-related kidney damage. A post-hoc analysis of 619 trial participants found that retatrutide 12 mg reduced the urine albumin-to-creatinine ratio (UACR) — a key marker of kidney stress — by 37.0% in people with type 2 diabetes and improved estimated glomerular filtration rate (eGFR) by 8.5 mL/min in the obesity group at 48 weeks[7]. These are preliminary post-hoc findings rather than pre-specified endpoints, so caution is warranted — but they hint that retatrutide's benefits reach well beyond the scale.
It is also important to state who is not yet a candidate. Retatrutide is not approved anywhere and is unavailable outside clinical trials. Anyone interested in the TRIUMPH program can search ClinicalTrials.gov for active enrollment sites.
Side Effects and Safety
The most common side effects follow the same pattern seen with other GLP-1-based therapies: gastrointestinal (GI) complaints concentrated in the early dose-escalation period. According to the meta-analysis by Abouelmagd et al., nausea occurred at a relative risk of 2.69 to 4.00 times the placebo rate, vomiting at 4.62 to 8.98 times, diarrhea at 1.64 to 2.51 times, and constipation at 4.17 to 4.41 times[4]. Those sound like large multipliers, but the absolute rates and severity are important context: events were classified as mild to moderate, and dropout rates due to GI side effects were comparable to other drugs in this class.
Two safety signals deserve attention. First, retatrutide produces a transient, dose-dependent increase in heart rate, a pattern also seen with semaglutide and tirzepatide[1]. The clinical significance in people without pre-existing cardiac conditions is still unclear and will be a key focus of phase 3 monitoring. Second, people on antihypertensive medications should note the 9.88 mmHg average systolic blood pressure reduction[4] — a benefit for most people with hypertension, but a potential over-correction risk if blood pressure is already well-controlled.
What the data do not show is also notable. There were no cases of severe hypoglycemia (dangerous low blood sugar) and no deaths attributed to retatrutide across the phase 2 program[2]. Liver enzyme elevations (ALT) were observed transiently but without progression to serious hepatotoxicity. Formal drug-drug interaction studies have not been completed, since the drug is still in phase 2 and 3 trials — which means prescribers will need to proceed cautiously with patients on complex medication regimens until that data exists.
How to Get Started (and What to Realistically Expect)
Retatrutide is not available at a pharmacy today. The most practical current access point is enrolling in an active TRIUMPH phase 3 trial. Search ClinicalTrials.gov for "retatrutide" to find recruiting sites. Trial participants receive the drug at no cost and close clinical monitoring throughout dose escalation.
If you are already on semaglutide or a similar drug and wondering how retatrutide compares, the evidence suggests greater average weight loss — with the same class of GI side effects and an added energy-expenditure mechanism that may cause fatigue in some people during early dose escalation. For more context on related drugs, see our semaglutide muscle loss prevention guide and oral semaglutide and Wegovy pill review.
When retatrutide reaches regulatory review, it will be weighed on efficacy versus the side effect profile and longer-term phase 3 safety data. Based on the phase 2 trajectory, a regulatory submission is unlikely before 2027, with approval contingent on how clearly TRIUMPH data read out. The science is advancing quickly, but regulatory timelines follow their own pace.
Frequently Asked Questions
What makes retatrutide different from semaglutide or tirzepatide?
Semaglutide activates one receptor (GLP-1R). Tirzepatide activates two (GLP-1R and GIPR). Retatrutide activates all three — GLP-1R, GIPR, and GCGR — adding a glucagon receptor component that increases energy expenditure. Phase 2 data suggest this produces greater average weight loss than either predecessor, though head-to-head trials have not been completed.
Is retatrutide safe?
Phase 2 data covering nearly 900 trial participants show a GI side effect profile similar to other GLP-1-based drugs — mostly nausea, vomiting, and constipation that is mild to moderate and concentrated during dose escalation. No severe hypoglycemia and no drug-related deaths were reported[2][4]. Phase 3 trials are underway to build a larger safety database before any regulatory submission.
Can I get retatrutide right now?
No. Retatrutide is not approved by any regulatory agency and is not available by prescription. The only current access point is enrollment in an active TRIUMPH phase 3 clinical trial. Search ClinicalTrials.gov for current recruiting sites.
How is retatrutide given?
It is administered as a once-weekly subcutaneous (under the skin) injection, starting at a low dose and escalating over several months to a maximum of 12 mg per week[6]. The half-life of approximately six days makes weekly dosing practical and keeps blood levels relatively stable.
Which group showed the largest results in trials?
People with obesity who do not have type 2 diabetes showed the largest weight reductions — averaging 24.2% at 48 weeks on the 12 mg dose[1]. People with type 2 diabetes showed slightly lower but still substantial weight loss (16.94%) alongside strong blood sugar improvements. People with fatty liver disease showed a dramatic 82.4% reduction in liver fat content[3].
References
[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2301972
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023. DOI: 10.1016/S0140-6736(23)01053-X
[3] Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. DOI: 10.1038/s41591-024-03018-2
[4] Abouelmagd K, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proceedings (Baylor University Medical Center). 2025. DOI: 10.1080/08998280.2025.2456441
[5] Tewari A, et al. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology. 2025. DOI: 10.1080/17512433.2025.2450254
[6] Kaur P, Misra A. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European Journal of Clinical Pharmacology. 2024. DOI: 10.1007/s00228-024-03646-0
[7] Heerspink HJL, et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney International Reports. 2025. DOI: 10.1016/j.ekir.2025.03.049
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
